Aesthetics Product Guide

Sanofi-aventis introduces Sculptra in Kuwait

Jim Marino — Mon, 09 Nov 2009 09:37:30 +0000

Sanofi-aventis pharmaceuticals have launched its highly anticipated anti-ageing drug, Sculptra in Kuwait following its approval from the Kuwait Ministry of Health earlier this year. Sculptra is an injectable treatment that consists of poly-L-lactic acid sterile suspension that is biocompatible and biodegradable making it easy for the body to absorb. Sculptra also stimulates the natural production of collagen in the skin.

TEI Biosciences launches SurgiMend(R) PRS for Breast Reconstruction

Jim Marino — Mon, 02 Nov 2009 09:19:45 +0000

TEI Biosciences Inc. has announced the introduction of its newest product line, SurgiMend® PRS for breast Reconstruction, a superior biologic mesh that featured at the ASPS Plastic Surgery 2009 conference in Seattle. TEI sells its products directly and through partnerships with some of the world’s major medical device companies. TEI’s marketed products include SurgiMend® for plastic and reconstructive surgery, breast reconstruction, muscle flap reinforcement, hernia repair, and abdominal wall reconstruction.

FDA recommendation on indoor tanning going unheeded

Jim Marino — Mon, 26 Oct 2009 15:50:23 +0000

The FDA has recommended but has not made it a requirement for indoor tanning bed operators to limit teens to three or fewer tanning bed sessions in the first week. Researchers from San Diego State University and colleagues have indicated that only about 11% indoor tanning bed operators did so, and 71% of tanning bed operators said they would allow a teen to tan seven days a week.

FDA gives nod to Solta Medical for aesthetic laser device

Jim Marino — Mon, 19 Oct 2009 14:40:55 +0000

Solta Medical Inc has received approval from the FDA of a new version of its popular Fraxel re:store Dual Laser System to clear pigmentation and other superficial skin conditions. The device with a 1550 nanometer (nm) wavelength already has the regulatory approval for skin resurfacing and treatment of pigmented lesions and certain other skin conditions.

Lumenis launches AcuPulse Fractional CO2 Laser System

Jim Marino — Mon, 12 Oct 2009 06:24:53 +0000

Lumenis Inc has launched the AcuPulse(TM) Fractional CO2 Laser System for aesthetic applications at the American Society of Dermatologic Surgery’s annual meeting in Phoenix. The AcuPulse(TM) gives physicians an affordable and efficient solution to their Pulsed Fractional Skin Resurfacing needs. Pulsed CO2 lasers are superior in the treatment of wrinkles, skin dyschromias, certain types of scars and the Lumenis’ AcuPulse(TM) brings its SuperPulse(TM) technology with the unmatched fractional scanning excellence of the Lumenis portfolio to give physicians an excellent solution for their practice.

FDA committees recommend approval of reformulated OxyContin

Jim Marino — Mon, 05 Oct 2009 06:54:20 +0000

Two FDA advisory committees voted in favor of the approval of Purdue Pharma’s reformulated version of long-acting OxyContin, despite some members’ concerns over the drug’s safety. The OxyContin drug designed to be abuse-deterrent. The reformulated version of OxyContin (oxycodone HCl) would be slightly safer than the current product, although its safety profile for the majority of users is still doubtful, according to David Margolis, the professor of dermatology and epidemiology at the University of Pennsylvania.

Sales of HydroPeptide soaring

Jim Marino — Tue, 29 Sep 2009 05:35:41 +0000

HydroPeptide Lash Longer Fuller Lusher is rapidly gaining popularity in the US as the new lash product due to its drug-free formulation and impressive results. HydroPeptide Lash’s popularity is partly due to the fact that the product does not contain “glaucoma type meds” like Latisse®, Peter Thomas Roth Lashes To Die for, Lilash or MD Lash Factor. The FDA is taking action against the other products because the “use of Age Intervention Eyelash may cause other adverse effects in certain people due to the bimatoprost, including macular edema (swelling of the retina) and uveitis (inflammation in the eye), which may lead to decreased vision.”

Azzalure approved by Spanish Medicines and Healthcare Products Agency

Jim Marino — Mon, 21 Sep 2009 05:59:34 +0000

Galderma, the leading pharmaceutical company in dermatology, and Ipsen, an international innovation-driven specialty pharmaceutical group, announced that Azzalure® (botulinum toxin type A manufactured by Ipsen), has received a marketing authorization in Spain from the Spanish Medicines and Healthcare Products Agency (AEMPS). Azzalure is a local muscle relaxant specifically developed for aesthetic use and has been approved for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown (vertical lines between the eyebrows), in adult men and women aged up to 65 years, when the severity of these lines has an important psychological impact on the patient.

Laser hair removal on rise in the UK: Harley Medical Group

Jim Marino — Mon, 14 Sep 2009 05:22:56 +0000

The Harley Medical Group has seen a 22% year on year rise in people grooming themselves in the pre-summer season. Laser hair removal has proven to be the most popular of all The Harley Medical Group non-surgical procedures across its 26 UK clinics. Laser hair removal usually requires six to eight courses of laser treatments. The most common areas in women are the face, neck, bikini line, underarms and legs. The most common areas in men are the face, neck, back and chest. The treatment can even be performed in a lunch break for busy businessmen.

SOLODYN approved in additional strengths

Jim Marino — Mon, 07 Sep 2009 08:39:25 +0000

The FDA has approved additional strengths of Medicis’ SOLODYN(R) (minocycline HCl, USP) Extended Release Tablets for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 12 years and more. The drug will now be available in 65mg and 115mg dosages also. “These additional strengths will complement the current SOLODYN lineup to offer physicians more precise weight-based dosing options, and make SOLODYN the first and only extended release minocycline with five FDA-approved dosing strengths. We believe physicians and patients will appreciate the value of this greater dosing precision,” Jonah Shacknai, Chairman and Chief Executive Officer of Medicis said.